Pulmatrix Completes Merger with Eos SENOLYTIX, Inc.

Pulmatrix, Inc. has announced the successful completion of its merger with Eos SENOLYTIX, Inc., a significant development for the company as it seeks to expand its operations in the pharmaceutical preparations sector. This merger, finalized on October 26, 2026, allows Pulmatrix to enhance its portfolio and market presence.

Founded in 2010 and based in Framingham, Massachusetts, Pulmatrix operates in the pharmaceutical preparations industry, focusing on developing innovative therapies. The company's stock is traded on the Nasdaq under the ticker symbol PULM. The recent merger with Eos, a Delaware corporation, is expected to strengthen Pulmatrix's capabilities and offerings.

The filing with the SEC indicates that Pulmatrix held a special meeting on October 26, 2026, where shareholders voted on several key proposals related to the merger. The proposals were outlined in the company's definitive proxy statement filed with the SEC on September 25, 2026.

During the special meeting, shareholders approved the issuance of shares representing more than 20% of Pulmatrix's outstanding shares to Eos stockholders and certain noteholders, as well as to Palladium, in connection with the merger. This proposal received a favorable vote, with 1,410,737 shares in favor, 172,166 against, and 22,400 abstaining.

Additionally, shareholders approved a reverse stock split of Pulmatrix common stock at a ratio determined by the board of directors, as well as an amendment to increase the number of authorized shares from 200 million to 250 million. These measures reflect the company's strategic planning to accommodate future growth and investment opportunities.

The merger is expected to have a positive impact on Pulmatrix's market position, potentially affecting its competitors in the pharmaceutical preparations industry. The successful completion of the merger demonstrates Pulmatrix's commitment to expanding its capabilities and enhancing shareholder value.

Looking ahead, the filing does not specify the immediate next steps for Pulmatrix following the merger. However, the successful integration of Eos into Pulmatrix's operations will likely be a focus as the company moves forward.